课题基金 / 基金详情

TREATMENTS FOR BENZODIAZEPINE DEPENDENCE

TREATMENTS FOR BENZODIAZEPINE DEPENDENCE
苯二氮卓依赖的治疗
批准号:
2119949
负责人:
JOHN D ROACHE
金额:
$19.13万
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
已结题
起止时间:
1994-09-01 至 1998-07-31

项目摘要

项目成果

JOHN D ROACHE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Benzodiazepines are safer and have lesser abuse potential than the barbiturates they replaced. However, dependence can occur with chronic therapy and result in withdrawal symptoms including anxiety, insomnia, tumor, muscle twitching, nausea, and perceptual distortions. Although benzodiazepines are considered modest reinforcers, such effects may combine with withdraws symptoms to sustain further drug taking. Because many withdrawal symptoms mimic anxiety disorder, it is difficult to know whether discontinuation symptoms represent disease reemergence or drug withdrawal. Also, because of the chronicity of anxiety disorders, it is not clear whether discontinuation failure or drug use relapse represents addictive behavior or continued pharmacotherapy. Whereas pharmacological factors involved in benzodiazepine physical dependence are well studied; behavioral factors related to "psychological dependence" have been rarely considered and are often ignored in discontinuation treatment. The proposed research addresses behavioral factors presumably involved in psychological dependence on benzodiazepines. Three studies examine patient compliance with benzodiazepine dose reduction and discontinuation by focusing on behavioral factors related to patient anxiety. These anxieties may be caused by an original disorder or by withdrawal reactions, but also may be related to psychological dependence on medication. Exp. #1 compares a short-term stabilization treatment prior to dose reduction with the effects of long-term dose stabilization and maintenance intended to acclimate the patients and appease their anxieties about dose reduction. Exp. #2 compares blind vs. open-label drug administration during dose reductions with the idea that blind dose- reduction may reduce anticipatory anxiety reactions. Exp. #3 compares control and cognitive/behavioral therapies to examine the effects of helping patients manage their anxiety levels during dose reduction or discontinuation. Measures for all studies include objective and subjective assessments of withdrawal, subject complaints, and medication compliance. These studies should: 1) clarify the role of psychological dependence in chronic benzodiazepine use; 2) help to optimize strategies for treating benzodiazepine dependence; 3) clarify behavioral determinants of persistent drug use in therapeutic drug dependence; 4) suggest interventions for other drug abusing patient populations (e.g., cocaine or opioid users) who also use benzodiazepines.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Alprazolam Abuse Liability in Post Traumatic Stress Disorder (PTSD)
Alprazolam Abuse Liability in Post Traumatic Stress Disorder (PTSD)
DIFFERENTIAL NEUROSTEROID RESPONSES IN PTSD AND ALCOHOL DEPENDENCE
DIFFERENTIAL NEUROSTEROID RESPONSES IN PTSD AND ALCOHOL DEPENDENCE
海外基金